PharmaVault
گنجینه اطلاعات داروسازی
The Pharmaceutical Information Vault
Excipient monograph · مونوگراف ماده جانبی
pharmavault.ir
Iron oxides
اکسید آهن
1Nonproprietary names
- USP–NFFerric Oxide
2Synonyms and trade names
CI 77491 (red), CI 77492 (yellow), CI 77499 (black); ferric oxide; ferrosoferric oxide; iron oxide red, yellow and black; pigment red 101; pigment yellow 42; pigment black 11; Sicopharm; Sicovit; E172
3Chemical name and CAS Registry Number
Iron(III) oxide (red); hydrated iron(III) oxide, iron oxide hydroxide (yellow); iron(II,III) oxide (black) · [—]
4Empirical formula and molecular weight
Fe2O3 (red); FeO(OH)·xH2O (yellow); Fe3O4 (black) · 159.69 (Fe2O3); 88.85 (FeOOH); 231.54 (Fe3O4)
5Functional category
Colouring agent
Typical concentrations: — · Dosage forms: Solid
6Applications in pharmaceutical formulation
Used as colourants and opacifiers in tablet film coatings, sugar coatings, hard and soft capsule shells and topical products, usually at low levels within the coating formulation. Blends of red, yellow and black oxides give a range of brown, orange and beige shades. They also provide some protection of light-sensitive drugs and are widely used in cosmetics.
7Description
Fine, odourless powders: red (haematite type), yellow (goethite type, hydrated) and black (magnetite type). Pharmaceutical grades are synthetic, which allows close control of colour, particle size and heavy-metal impurities.
8Typical properties
- Solubility
- practically insoluble in water and organic solvents; soluble in hot concentrated mineral acids
- Density
- high, about 4–5 g/cm³ depending on type
- Thermal behaviour
- yellow oxide loses water above about 200 °C and turns red; black oxide oxidises to red on strong heating in air
- Magnetism
- black oxide is strongly magnetic
9Stability and storage conditions
Stable to light and to the conditions of normal storage and processing. Store in a well-closed container in a cool, dry place.
10Incompatibilities
Generally inert, but traces of soluble iron can catalyse the oxidation of sensitive drugs and may form coloured complexes with phenolic compounds. Strong acids dissolve them.
11Method of manufacture
Produced synthetically, for example by precipitation from iron(II) salt solutions followed by oxidation (yellow and black), by calcination of yellow or black oxide (red), or by the reduction of nitrobenzene with iron (Laux process).
12Safety
Considered non-toxic and non-irritant at the levels used as colourants; absorption of iron from them is very limited. Inhalation of the dust over long periods should be avoided.
13Handling precautions
Observe normal precautions for the quantity handled. Use a dust mask and eye protection; the powders stain skin and surfaces.
14Regulatory status
Accepted as a food colour in Europe (E172), re-evaluated by EFSA. In the USA synthetic iron oxides are permitted as colour additives in drugs, with ingested drugs limited to 5 mg of elemental iron per daily dose. Included in the FDA Inactive Ingredient Database (oral capsules and tablets; topical preparations) and in non-parenteral medicines licensed in Europe.
15Related substances
Titanium dioxide; aluminium lakes; calcium carbonate (as opacifier).
16Comments
With the restriction of titanium dioxide as a food additive in the EU, iron oxides are increasingly used in combination with other opacifiers in film coatings. Colour of the final coat depends on particle size and dispersion, so pigment suspensions should be milled or homogenised and the colour checked against a standard.